{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:07:10Z","timestamp":1791328030821,"version":"4.3.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1124\/jpet.116.235556","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T22:03:27Z","timestamp":1466201007000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice"],"prefix":"10.1016","volume":"358","author":[{"given":"Kurt","family":"Giles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Condello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Dugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Elepano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenheng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Michael","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley B.","family":"Prusiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.235556_bib1","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","article-title":"Evaluation of quinacrine treatment for prion diseases","volume":"77","author":"Barret","year":"2003","journal-title":"J Virol"},{"issue":"Suppl 1","key":"10.1124\/jpet.116.235556_bib2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/infdis\/jiu656","article-title":"Use of a 2-aminothiazole to treat chronic wasting disease in transgenic mice","volume":"212","author":"Berry","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1124\/jpet.116.235556_bib3","doi-asserted-by":"crossref","first-page":"E4160","DOI":"10.1073\/pnas.1317164110","article-title":"Drug resistance confounding prion therapeutics","volume":"110","author":"Berry","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib4","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1128\/jvi.68.12.7859-7868.1994","article-title":"Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy","volume":"68","author":"Bessen","year":"1994","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/jvi.62.5.1558-1564.1988","article-title":"Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins","volume":"62","author":"Butler","year":"1988","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.it.2014.10.003","article-title":"Prion-like polymerization as a signaling mechanism","volume":"35","author":"Cai","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1124\/jpet.116.235556_bib7","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1073\/pnas.91.12.5690","article-title":"Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib8","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1073\/pnas.1604478113","article-title":"Luminidependens (LD) is an Arabidopsis protein with prion behavior","volume":"113","author":"Chakrabortee","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1138718","article-title":"A general model of prion strains and their pathogenicity","volume":"318","author":"Collinge","year":"2007","journal-title":"Science"},{"key":"10.1124\/jpet.116.235556_bib10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","author":"Collinge","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.116.235556_bib11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.10336","article-title":"Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model","volume":"52","author":"Collins","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.116.235556_bib12","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/JVI.78.10.4999-5006.2004","article-title":"Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models","volume":"78","author":"Doh-ura","year":"2004","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib13","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1128\/jvi.74.10.4894-4897.2000","article-title":"Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation","volume":"74","author":"Doh-ura","year":"2000","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/jm101250y","article-title":"2-Aminothiazoles as therapeutic leads for prion diseases","volume":"54","author":"Gallardo-Godoy","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.235556_bib15","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease","volume":"81","author":"Geschwind","year":"2013","journal-title":"Neurology"},{"key":"10.1124\/jpet.116.235556_bib16","doi-asserted-by":"crossref","first-page":"e1000673","DOI":"10.1371\/journal.ppat.1000673","article-title":"Continuous quinacrine treatment results in the formation of drug-resistant prions","volume":"5","author":"Ghaemmaghami","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1124\/jpet.116.235556_bib17","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/JVI.02145-09","article-title":"Discovery of 2-aminothiazoles as potent antiprion compounds","volume":"84","author":"Ghaemmaghami","year":"2010","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib18","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1074\/jbc.M109.045112","article-title":"Chemical induction of misfolded prion protein conformers in cell culture","volume":"285","author":"Ghaemmaghami","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235556_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.115.224659","article-title":"Different 2-aminothiazole therapeutics produce distinct patterns of scrapie prion neuropathology in mouse brains","volume":"355","author":"Giles","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.235556_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ana.22104","article-title":"Human prion strain selection in transgenic mice","volume":"68","author":"Giles","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1124\/jpet.116.235556_bib21","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","article-title":"Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects","volume":"63","author":"Ha\u00efk","year":"2004","journal-title":"Neurology"},{"key":"10.1124\/jpet.116.235556_bib22","doi-asserted-by":"crossref","first-page":"12889","DOI":"10.1128\/JVI.01563-07","article-title":"Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner","volume":"81","author":"Kawasaki","year":"2007","journal-title":"J Virol"},{"key":"10.1124\/jpet.116.235556_bib23","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease","volume":"98","author":"Korth","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/ml300454k","article-title":"Optimization of arylamides as novel, potent and brain-penetrant antiprion lead compounds","volume":"4","author":"Li","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.116.235556_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cmdc.201300007","article-title":"2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease","volume":"8","author":"Li","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.116.235556_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/jpet.113.205799","article-title":"Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice","volume":"347","author":"Lu","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.235556_bib27","doi-asserted-by":"crossref","first-page":"20908","DOI":"10.1073\/pnas.0710054104","article-title":"Prion strain discrimination in cell culture: the cell panel assay","volume":"104","author":"Mahal","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib28","doi-asserted-by":"crossref","first-page":"e1003158","DOI":"10.1371\/journal.ppat.1003158","article-title":"Acquisition of drug resistance and dependence by prions","volume":"9","author":"Oelschlegel","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1124\/jpet.116.235556_bib29","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib30","unstructured":"Rasband WS (1997\u20132014) ImageJ, U.S. National Institutes of Health, Bethesda, MD."},{"key":"10.1124\/jpet.116.235556_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-cellbio-100913-013409","article-title":"Prions: what are they good for?","volume":"31","author":"Si","year":"2015","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1124\/jpet.116.235556_bib32","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1016\/j.bmc.2013.09.022","article-title":"Antiprion compounds that reduce PrPSc levels in dividing and stationary-phase cells","volume":"21","author":"Silber","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.116.235556_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s11095-012-0912-4","article-title":"Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice","volume":"30","author":"Silber","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.116.235556_bib34","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1126\/science.274.5295.2079","article-title":"Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity","volume":"274","author":"Telling","year":"1996","journal-title":"Science"},{"key":"10.1124\/jpet.116.235556_bib35","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.1073\/pnas.91.21.9936","article-title":"Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein","volume":"91","author":"Telling","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.235556_bib36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.116.235556_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-071714-033828","article-title":"Neurodegenerative diseases: expanding the prion concept","volume":"38","author":"Walker","year":"2015","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/jpet.116.235556_bib38","doi-asserted-by":"crossref","first-page":"19841","DOI":"10.1074\/jbc.R114.550707","article-title":"Mouse models for studying the formation and propagation of prions","volume":"289","author":"Watts","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.235556_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MMBR.00041-14","article-title":"Yeast prions: structure, biology, and prion-handling systems","volume":"79","author":"Wickner","year":"2015","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1124\/jpet.116.235556_bib40","doi-asserted-by":"crossref","first-page":"9413","DOI":"10.1128\/JVI.72.11.9413-9418.1998","article-title":"Mapping the prion protein using recombinant antibodies","volume":"72","author":"Williamson","year":"1998","journal-title":"J Virol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.235556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:47:50Z","timestamp":1739976470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524193950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0022356524193950"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.235556","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.235556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}